Company Overview

Alpa Laboratories Limited, incorporated in 1988, is a prominent pharmaceutical company headquartered in Indore, India. Founded by Mahendra Singh Chawla, Purushottam R. Patel, and Pravin C. Shah, the company has established itself as a WHO-GMP and ISO 9001:2000 certified manufacturer of drugs and chemicals. Alpa Laboratories specializes in producing a diverse range of Pharmaceutical Finished Dosage Forms, both under its own brand and for other domestic and international pharmaceutical firms.

The company's extensive product portfolio covers ethical, generic, and over-the-counter (OTC) drugs for both human and veterinary use. This includes formulations like injections, tablets, capsules, eye and ear drops, ointments, creams, and gels. Alpa Laboratories offers drugs across various therapeutic categories, such as anti-infectives (antibacterial, antibiotics, antifungals, antiprotozoals, antivirals), analgesics, anti-inflammatory drugs, cough and cold remedies, and cardiovascular drugs.

Market Position and Financial Snapshot

Alpa Laboratories Limited (ALPA) holds a market capitalization of ₹227.53 Crore as of May 2025, with a reported market capitalization of ₹2.27 Billion. The company's market cap has seen a 4.74% increase over the last week. Operating within the pharmaceutical sector, Alpa Laboratories is classified under the specialty and generic drug manufacturers category.

Key Financial Metrics

Based on the latest available data (as of May 2025), here are the key financial indicators for Alpa Laboratories:

- Revenue (TTM): ₹96.14 Crore (Trailing 12 Months)

- Annual Revenue: ₹112 Crore

- Net Profit (TTM): ₹19 Crore (Profit After Tax)

- PE Ratio: 8.98 (Current), 9.02 (Latest as of May 20, 2025)

- PB Ratio: 1.38 (Current), 0.72 (Latest as of May 20, 2025)

- ROE: 12.1%

- ROCE: 15.8%

Recent Financial Performance

Alpa Laboratories Ltd reported a significant revenue jump of 53.68% year-on-year to ₹42.40 Crore in Q4 FY2024-2025. Quarter-on-quarter, revenue grew by 21.32%. However, the Q4 FY25 results indicated challenges, with net profit falling by -159.72% year-on-year to ₹-2.12 Crore. Quarterly net profit also saw a decline of -123.82%.

On a longer-term basis, the company has demonstrated good profit growth, achieving a 49.2% CAGR over the last 5 years. However, sales growth over the past five years has been modest at 5.66%. The company has shown an outstanding annual revenue growth of 21% and a great pre-tax margin of 19%, with a good ROE of 11%.

Financial Strength and Debt Position

A key strength of Alpa Laboratories is its robust balance sheet. The company has successfully reduced its debt and is currently debt-free. This strong financial position allows for stable earnings growth across business cycles and provides significant financial flexibility and reduced risk for investors.

Corporate Structure and Management

The key management includes Mahendra Singh Chawla as Chairman and Srashti Chopra as Company Secretary. Promoter Holding stands at 57.3%, indicating strong confidence in the business's prospects. As of May 20, 2025, the company employed 410 individuals.

Manufacturing and Operations

Alpa Laboratories operates a comprehensive manufacturing infrastructure. Its Unit-II, dedicated to oral solid dosage manufacturing with a focus on containment products like oral hormonal and other high-potency formulations, became operational in the Pithampur Industrial Area in 2012. The company has an established product-marketing network reaching both metro and mini-metro cities through distributors and dealers nationwide. Its business operations are categorized into four divisions: Branded Generic Division, Veterinary Division, Exports Division, and Contract Manufacturing Division.

Stock Market Performance

Over the past 6 months, the Alpa Laboratories share price has decreased by 4.14%. In the last year, it has increased by 17.76%. Over a 3-year period, Alpa Laboratories Ltd has provided a return of 24.85%. The stock reached its all-time high on September 30, 2024, at ₹144.50, and its all-time low was recorded on June 13, 2013, at ₹5.10.

Investment Considerations

Alpa Laboratories Ltd does not currently pay dividends to its shareholders. While the company consistently reports profits, the absence of dividend payouts might be a concern for income-focused investors. However, the company's debt-free status and its manufacturing capabilities within the growing pharmaceutical sector offer potential opportunities for growth-oriented investors.

The Indian pharmaceutical industry continues to benefit from increasing healthcare awareness, an aging demographic, and expanding export opportunities. This positions companies like Alpa Laboratories, with their diversified product portfolio spanning human and veterinary medicines, to potentially capitalize on these industry trends.